Feed CODX
CO

Co-Diagnostics, Inc.

CODX · NASDAQ

$1.01 +2.03% (+$0.02)
1M -17.21%
Market Cap $1.13M
P/E Ratio -
Div. Yield -
ROE 210.99%

Bulios Fair Price

$1.14

12.9% upside

Preț actual

$1.01

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile CODX sunt în prezent subevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Weak
2/9
Valuation
94 /100
Cheap
P/S 1.56x
P/B 0.09x
P/E N/A
Growth
0 /100
Declining
Rev. growth 73.70%
Book val. growth 43.52%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 8.07%
Net margin 6,523.04%
Op. margin 4,170.14%
Quality
1 /100
Poor
ROIC 200.40%
ROE 210.99%
ROA 283.63%
Debt
97 /100
Low
Debt/Equity 0.14x
Current ratio 1.81x
Int. coverage N/A
Stability
15 /100
Unstable
Beta 2.86x
Rev. volatility 22.93%
EPS volatility 96.08%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre CODX
Online

Despre companie

Co-Diagnostics, Inc. (CODX) is an American biotechnology company specializing in the development and manufacturing of diagnostic tests and reagent kits for the detection of various infectious diseases. The company focuses on innovative molecular diagnostic technologies that enable rapid and accurate determination of pathogens in patient samples. Its diagnostic tools are applied in the detection of viral, bacterial, and parasitic infections, serving both as diagnostic and monitoring solutions for diseases. With its advanced diagnostic technologies, Co-Diagnostics can contribute to improving healthcare and reducing the spread of infectious diseases. The company continually emphasizes research and development of new diagnostic tests to meet the needs of the medical community. Co-Diagnostics, Inc. (CODX) shares may be an attractive investment opportunity for investors interested in the healthcare sector and seeking an investment in a company dedicated to innovative diagnostic technologies.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Dwight Egan

Employees

115

Headquarters

Salt Lake City

Evenimente viitoare

16 NOV.

Earnings

Upcoming earnings report

55d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.